In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placeb...
The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...
AbstractIn the FREEDOM study, denosumab treatment (60mg every 6months) decreased bone resorption, in...
FREEDOM was a phase 3 trial in 7808 women aged 60-90 yr with postmenopausal osteoporosis. Subjects r...
Women with osteoporosis treated for 36 months with twice-yearly injections of denosumab sustained fe...
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased ris...
In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
Summary Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ra...
In the randomized, placebo‐controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
Objective: The aim of this study was to report the effects of denosumab on radius cortical and trabe...
Background/Purpose: The trabecular bone score (TBS), a novel graylevel texture index determined from...
Hip fractures account for over one-half the morbidity, mortality, and cost associated with osteoporo...
Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...
The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...
AbstractIn the FREEDOM study, denosumab treatment (60mg every 6months) decreased bone resorption, in...
FREEDOM was a phase 3 trial in 7808 women aged 60-90 yr with postmenopausal osteoporosis. Subjects r...
Women with osteoporosis treated for 36 months with twice-yearly injections of denosumab sustained fe...
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased ris...
In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
Summary Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ra...
In the randomized, placebo‐controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal...
Objective: The aim of this study was to report the effects of denosumab on radius cortical and trabe...
Background/Purpose: The trabecular bone score (TBS), a novel graylevel texture index determined from...
Hip fractures account for over one-half the morbidity, mortality, and cost associated with osteoporo...
Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...
The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for trea...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that...